What are the complications of endoscopic retrograde cholangiopancreatography (ERCP)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

ERCP Complications

The overall complication rate for ERCP ranges from 4.0% to 6.85%, with post-ERCP pancreatitis being the most common and feared complication, occurring in 3.47-3.6% of procedures. 1

Major Complications

Post-ERCP Pancreatitis (PEP)

  • Most frequent complication with incidence ranging from 1-7% (up to 17.2% in some series) 1, 2
  • Risk factors include:
    • Female sex (OR: 2.6)
    • Guidewire in pancreatic duct (OR: 8.2)
    • Native papilla (vs. previous sphincterotomy)
    • Prolonged papilla contact time
    • Therapeutic procedures: brush cytology, sphincterotomy, stenting, dilation
    • Precut biliary and pancreatic sphincterotomy 1

Prevention strategy (strong recommendation):

  • Rectal NSAIDs (100 mg diclofenac or indomethacin) immediately before or after ERCP in all patients without contraindication
  • Prophylactic 5-Fr pancreatic stent placement in high-risk cases 1

Cholangitis

  • Incidence: 0.25-9.7% 1, 2
  • Higher risk in PSC patients and incomplete drainage
  • Prevention: Routine prophylactic antibiotics recommended before ERCP in high-risk patients (strong recommendation) 1
  • Prophylactic antibiotics reduce:
    • Cholangitis (RR: 0.54)
    • Septicemia (RR: 0.35)
    • Bacteremia (RR: 0.50) 1

Bleeding

  • Incidence: 0.1-3.9% after sphincterotomy 3, 4
  • Risk factors:
    • Bleeding observed during procedure
    • Coagulopathy
    • Anticoagulant therapy within 3 days post-procedure
    • Active cholangitis
    • Low endoscopist case volume 3
  • Prevention: Use blended current (not pure-cutting) for sphincterotomy to reduce hemorrhage risk 3

Perforation

  • Incidence: 1.1% 4
  • Types classified by anatomical location:
    • Type I: Periampullary
    • Type II: Perivaterian (duodenal wall injury)
    • Type III: Bile duct injury
  • Associated with significant morbidity and mortality requiring prompt recognition 5, 6
  • Contrast extravasation is a specific risk in PSC patients 1

Cholecystitis

  • Incidence: 5.5% 4
  • Associated with sphincterotomy and inexperienced endoscopists
  • Stent removal can trigger gallbladder hydrops 1

Risk Stratification

Patient-related factors (non-modifiable but allow closer monitoring):

  • Advanced age
  • Female gender
  • Previous ERCP history
  • Previous pancreatitis
  • Non-dilated extrahepatic bile ducts 2, 5

Procedure-related factors:

  • Sphincterotomy increases all complication rates 4
  • Stent placement
  • Hilar obstruction
  • Prolonged or complex procedures
  • Basket use 4

Operator-related factors:

  • Inexperienced endoscopists show higher complication rates 4
  • ERCP in PSC patients should be performed by experienced pancreaticobiliary endoscopists (strong recommendation) 1

Special Considerations

PSC patients face elevated risk:

  • Overall adverse event rate: 1.8-18.4% (higher than general ERCP population) 1
  • Specific risks: pancreatitis, cholangitis, contrast extravasation
  • Cannulation success: 88.2% in largest series 1
  • Technical challenges: papilla retraction, altered endoscope position from left lobe hypertrophy 1

Critical Pitfalls

  • Guidewire-assisted cannulation technique is superior to contrast-assisted, increasing primary cannulation rate while reducing PEP risk 1
  • Bile duct contamination occurs in >86% of cases with concerning antibiotic resistance patterns, particularly Enterobacteriaceae (29% of bloodstream infections) and Enterococci (22%) 2
  • Procedure-related mortality: 0.26-1.0% 2
  • Intra-abdominal collections detected on CT in 51.2% of complicated cases 2

Related Questions

After endoscopic retrograde cholangiopancreatography (ERCP) with sphincterotomy, when should clopidogrel and warfarin be resumed?
What is the management of a 47-year-old patient with chronic left upper quadrant (LUQ) pain, sludge on computed tomography (CT) and magnetic resonance cholangiopancreatography (MRCP) showing mid common bile duct (CBD) dilation and distal CBD stricture, with normal liver function tests (LFTs), and a possible choledochocele, who underwent endoscopic retrograde cholangiopancreatography (ERCP) with dilation of the CBD stricture and removal of sludge/debris, resulting in pain resolution?
Is endoscopic retrograde cholangiopancreatography (ERCP) an emergency treatment for a perforated gallbladder?
What is the post-ERCP (Endoscopic Retrograde Cholangiopancreatography) management plan for a patient with a history of acute pancreatitis and cholelithiasis?
What are the recommended prevention and management strategies for post‑ERCP pancreatitis?
Is it safe to combine Azstarys (serdexmethylphenidate/dexmethylphenidate) with Vyvanse (lisdexamfetamine)?
What is refeeding syndrome and how should it be managed?
What are the possible diagnoses for a 48-year-old patient presenting with severe cognitive impairment (brain fog), marked fatigue, and diffuse myalgias?
Does Lacosamide (VIMPAT) require a dose adjustment when switching from intravenous to oral administration, including when given via a percutaneous endoscopic gastrostomy (PEG) tube?
What is the recommended treatment for a 48-year-old patient with myalgic encephalomyelitis (ME) and chronic fatigue syndrome (CFS)?
What is the appropriate evaluation and management for an isolated elevated γ‑glutamyl transferase (GGT) with normal aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.